18 Ovarian Cancer 1 1 0 10 10 174 http://clinicaltrials.dfhcc.harvard.edu/trials/174 Platinum Resistant Ovarian Cancer Evaluation of Doxil and EC145 Combination Therapy The objective of this study is to compare progression-free survival (PFS), based upon investigator assessment using RECIST and clinical findings, in subjects with platinum-resistant ovarian cancer who receive combination therapy with EC145 and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) with that in subjects with platinum-resistant ovarian cancer who receive PLD alone. Recruiting 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer Phase 2 177 http://clinicaltrials.dfhcc.harvard.edu/trials/177 A Study of GDC-0449 (Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission The proposed study is a Phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial of GDC-0449 in patients with ovarian cancer in a second or third complete remission. Patients will be randomized in a 1:1 ratio to either GDC-0449 or placebo. Randomization will be stratified based on whether their cancer is in a second or third complete remission. Recruiting 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer Phase 2 246 http://clinicaltrials.dfhcc.harvard.edu/trials/246 Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer The purpose of this study is to evaluate how the participant's disease (ovarian, serous or fallopian tube cancer) responds to additional treatment with Avastin (bevacizumab). Participant's have already received Avastin as part of maintenance therapy for their cancer. Maintenance therapy is a medical therapy that is given to people to prevent a relapse. However, cancer may return after maintenance therapy. This research study hopes to determine whether additional treatment with Avastin will be effective in treating the participant's cancer. Recruiting 7 Endometrial/Uterine Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/7-endometrial-uterine-cancer 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer Phase 2 247 http://clinicaltrials.dfhcc.harvard.edu/trials/247 Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma The purpose of this study is to determine the effectiveness of sunitinib on participants with ovarian, fallopian tube or peritoneal cancer. Sunitinib is a newly discovered drug that may stop cancer cells from growing by blocking the blood supply to the tumor. Recruiting 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer 7 Endometrial/Uterine Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/7-endometrial-uterine-cancer Phase 2 23 http://clinicaltrials.dfhcc.harvard.edu/trials/23 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers This research study is evaluating a drug called avastin in combination with standard radiation as a possible treatment for treatment for recurrent pelvic-confined gynecological cancer (i.e. endometrial, cervical, vulvar, ovarian or vaginal cancers). Recruiting 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer 4 Cervical Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/4-cervical-cancer Phase 2 1428 http://clinicaltrials.dfhcc.harvard.edu/trials/1428 A Study of Liposomal Doxorubicin With or Without IMC-3G3 in Platinum-refractory or Resistant Advanced Ovarian Cancer The purpose of this study is to determine if patients with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with IMC-3G3 in combination with Liposomal Doxorubicin then when treated with Liposomal Doxorubicin alone. Recruiting 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer Phase 2 117 http://clinicaltrials.dfhcc.harvard.edu/trials/117 Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function The purpose of this study is to ask youn women diagnosed with ovarian cancer who have undergone surgery that will allow them to have children in the future, on issues such as: education about their options to keep their ability to have children, after-chemotherapy treatment decision making, and reproductive history. The second purpose is to determine the effect of an early diagnosis of ovarian cancer on the sexual functioning of women. Recruiting 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer N/A 1223 http://clinicaltrials.dfhcc.harvard.edu/trials/1223 Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification. The primary objective of this trial is to estimate the objective response rate for patients with tumors harbouring EGFR and/or HER2 gene amplifications or EGFR activating mutations who will be treated with BIBW 2992. Recruiting 1 Bladder Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/1-bladder-cancer 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer 7 Endometrial/Uterine Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/7-endometrial-uterine-cancer 1230 http://clinicaltrials.dfhcc.harvard.edu/trials/1230 Assessment of Efficacy of AZD2281 in Platinum Sensitive Serous Ovarian Cancer The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy. Recruiting 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer 1381 http://clinicaltrials.dfhcc.harvard.edu/trials/1381 A Study of Chemotherapy Treatment for Patients With Ovarian Cancer The primary objective is to determine whether LY573636 is effective in treating platinum-resistant ovarian cancer. Patients will receive an intravenous infusion of study drug once every 28 days. CT scans and CA-125 tests will be done before the first dose and then after every other treatment. Recruiting 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer